These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10030499)

  • 21. The National Institutes of Health and the Best Pharmaceuticals for Children Act.
    Zajicek A
    Paediatr Drugs; 2009; 11(1):45-7. PubMed ID: 19127953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
    Novak E; Allen PJ
    Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 24. The pediatric research equity act and oncology.
    Hirschfeld S
    Pediatr Blood Cancer; 2004 Aug; 43(2):99-102. PubMed ID: 15236272
    [No Abstract]   [Full Text] [Related]  

  • 25. Tricky FDA debate: should a risky drug be approved again?
    Mathews AW; Westphal SP
    Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879
    [No Abstract]   [Full Text] [Related]  

  • 26. Rules set for dissemination of off-label-use information.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500
    [No Abstract]   [Full Text] [Related]  

  • 27. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 28. Black box warnings: what do they mean to pharmacists and patients.
    Martin CM; Borgelt L
    Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug safety and effectiveness in children.
    Guharoy R
    Am J Health Syst Pharm; 2002 Aug; 59(16):1569-70. PubMed ID: 12185835
    [No Abstract]   [Full Text] [Related]  

  • 30. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.
    Hudgins JD; Bacho MA; Olsen KL; Bourgeois FT
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):161-167. PubMed ID: 29148107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA, off-label use, and informed consent: debunking myths and misconceptions.
    Beck JM; Azari ED
    Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA homes in on counterfeit and imported drugs.
    Ault A
    Lancet; 2003 Oct; 362(9391):1208. PubMed ID: 14570041
    [No Abstract]   [Full Text] [Related]  

  • 33. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 34. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
    Field MJ; Ellinger LK; Boat TF
    Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-label drug use.
    Dooley AG
    Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258
    [No Abstract]   [Full Text] [Related]  

  • 36. Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs.
    Naci H; Guan X; Woloshin S; Xu Z; Wagner AK
    JAMA Intern Med; 2021 Nov; 181(11):1521-1522. PubMed ID: 34251420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction to the new prescription drug labeling by the Food and Drug Administration.
    Lal R; Kremzner M
    Am J Health Syst Pharm; 2007 Dec; 64(23):2488-94. PubMed ID: 18029957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reimbursement for unlabeled medication use.
    Brushwood DB
    Am J Health Syst Pharm; 1999 Feb; 56(3):257-9. PubMed ID: 10030514
    [No Abstract]   [Full Text] [Related]  

  • 39. The Food and Drug Administration's paternalism.
    Somberg JC
    Am J Ther; 2010; 17(6):533-4. PubMed ID: 21060255
    [No Abstract]   [Full Text] [Related]  

  • 40. US FDA calls for technological attack on drug counterfeiting.
    Ault A
    Lancet; 2004 Feb; 363(9410):714. PubMed ID: 15005089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.